Table of Contents
1 Executive Summary
2 Introduction to Monoclonal Antibodies
2.1 Antibodies
2.1.1 Function of Antibodies
2.1.2 Structure of Antibodies
2.2 Monoclonal Antibody Therapeutics
2.2.1 Polyclonal and Monoclonal Antibodies
2.2.2 Murine Monoclonal Antibodies
2.2.3 Chimeric and Humanised Monoclonal Antibodies
2.2.4 Fully-Human Monoclonal Antibodies
2.2.5 Currently-Approved Monoclonal Antibody Therapeutics
3 The Global Monoclonal Antibodies Market, 2009-2024
3.1 Monoclonal Antibodies: Market Overview
3.1.1 Size of Monoclonal Antibody Market in 2008
3.1.2 Monoclonal Antibodies: Revenue Analysis by Therapeutic Area, 2008
3.1.3 Leading Monoclonal Antibodies: Revenue Analysis, 2008
3.1.4 Monoclonal Antibodies: Revenue Analysis by Type, 2008
3.1.5 Monoclonal Antibodies: Revenue Analysis by Company, 2008
3.1.6 Global Monoclonal Antibody Market Forecast, 2009-2014
3.1.7 Monoclonal Antibodies Sales Forecast, 2014-2024
3.2 The Oncology Monoclonal Antibodies Market
3.2.1 Leading Oncology Monoclonal Antibodies: Revenue Analysis, 2008
3.2.2 Oncology Monoclonal Antibodies: Revenue Analysis by Type, 2008
3.2.3 Oncology Monoclonal Antibodies: Revenue Analysis by Company, 2008
3.2.4 Continuing High Growth: Oncology Monoclonal Antibodies, 2009-2014
3.2.5 Oncology Monoclonal Antibodies Sales Forecast, 2014-2024
3.3 MabThera/Rituxan
3.3.1 MabThera/Rituxan: The First Blockbuster Monoclonal Antibody
3.3.2 MabThera/Rituxan Revenue Analysis, 2008
3.3.3 MabThera/Rituxan Market Forecast, 2009-2014
3.3.4 MabThera/Rituxan Long-Term Prospects, 2014-2024
3.3.5 New Oncology Growth Areas for MabThera/Rituxan, 2009-2014
3.3.6 Intensifying Competition: MabThera/Rituxan in Oncology, 2014-2024
3.4 Avastin
3.4.1 Avastin: A Cancer Blockbuster Set To Reach $10bn
3.4.2 Avastin Revenue Analysis, 2008
3.4.3 Avastin 2009-2014: 'a Pipeline-In-One'
3.4.4 The Competitive Landscape for Avastin, 2009-2014
3.4.5 Avastin Market Forecast, 2009-2014
3.4.6 Outlook for Avastin: Sales Forecast, 2014-2024
3.5 Herceptin
3.5.1 Herceptin Successfully Targets HER2-Positive Patients
3.5.2 Herceptin Revenue Analysis, 2008
3.5.3 Herceptin Market Forecast, 2009-2014
3.5.4 Increased Competition for Herceptin, 2014-2024
3.6 Erbitux
3.6.1 Erbitux's Oncology Indications
3.6.2 Erbitux Revenue Analysis, 2008
3.6.3 Opportunity in Head and Neck Cancer and New Indications for Erbitux
3.6.4 Erbitux Sales Forecast, 2009-2024
3.7 Other Oncology Monoclonal Antibodies
3.7.1 Vectibix
3.7.2 Vectibix Revenue Analysis, 2008
3.7.3 Campath/MabCampath
3.7.4 Campath/MabCampath Revenue Analysis
3.7.5 Mylotarg
3.7.6 Zevalin
3.7.7 Bexxar
3.7.8 TheraCIM (Nimotuzumab)
3.7.9 Removab
3.8 The Autoimmune Disorder Monoclonal Antibodies Market
3.8.1 Leading Autoimmune Disorder Monoclonal Antibodies: Revenue Analysis, 2008
3.8.2 Autoimmune Disorder Monoclonal Antibodies: Revenue Analysis by Type, 2008
3.8.3 Autoimmune Disorder Monoclonal Antibodies: Revenue Analysis by Company, 2008
3.8.4 Humira and Novel Antibodies Drive Autoimmune Monoclonal Market, 2009-2014
3.8.5 Autoimmune Disorder Monoclonal Antibodies Sales Forecast, 2014-2024
3.9 Remicade
3.9.1 Remicade: Leading Anti-TNF Drug
3.9.2 Remicade Revenue Analysis, 2008
3.9.3 Remicade's Competitors
3.9.4 Imminent Increase in Competition for Remicade
3.9.5 Remicade Market Forecast, 2009-2014
3.9.6 Remicade Market Forecast, 2015-2025
3.10 Humira
3.10.1 Humira: First Fully-Human Monoclonal Antibody on Market
3.10.2 Humira Revenue Analysis, 2008
3.10.3 Humira's Market Potential, 2009-2014
3.10.4 Humira Sales Forecast, 2015-2024
3.11 Novel Anti-TNF Monoclonal Antibodies
3.11.1 Cimzia: Newly-Approved Fully-Human Monoclonal Antibody
3.11.2 Cimzia Sales Forecast, 2009-2024
3.11.3 Simponi
3.11.4 Simponi Sales Forecast, 2009-2024
3.12 MabThera/Rituxan for Autoimmune Disorders
3.12.1 MabThera/Rituxan: Not Just for Oncology
3.12.2 Raft of Competitors for MabThera/Rituxan in Autoimmune Disorders, 2009-2024
3.13 Xolair
3.13.1 Genentech's Asthma Monoclonal Antibody: Xolair
3.13.2 Xolair Revenue Analysis, 2008
3.13.3 Xolair Sales Forecast, 2009-2014
3.14 Tysabri
3.14.1 Tysabri
3.14.2 Tysabri Revenue Analysis, 2008
3.14.3 Tysabri Sales Forecast, 2009-2024
3.15 Other Autoimmune Disorder Monoclonal Antibodies
3.15.1 Soliris
3.15.2 Soliris Revenue Analysis, 2008
3.15.3 Raptiva
3.15.4 Raptiva Revenue Analysis, 2008
3.15.5 Raptiva Withdrawn from Market in 2009
3.15.6 Simulect
3.15.7 Actemra/RoActemra
3.15.8 Zenapax
3.15.9 Orthoclone OKT3
3.15.10 Stelara
3.15.11 Simponi
3.16 Other Monoclonal Antibodies (Non-Oncology/Autoimmune Disorders)
3.16.1 Other Leading Monoclonal Antibodies: Revenue Analysis, 2008
3.16.2 Other Monoclonal Antibodies Sales Forecast, 2009-2024
3.17 Lucentis
3.17.1 Lucentis: Serendipitous Antibody Fragment for Ophthalmology
3.17.2 Lucentis Revenue Analysis, 2008
3.17.3 Impact of Off-Label Avastin on Lucentis, 2009-2024
3.17.4 Lucentis Sales Forecast, 2009-2014
3.17.5 Lucentis Sales Forecast, 2014-2024
3.18 Synagis
3.18.1 Synagis: Sole Blockbuster Respiratory Disorder Monoclonal Antibody
3.18.2 Synagis Revenue Analysis, 2008
3.18.3 Synagis/Motavizumab Market Forecast, 2009-2024
3.19 ReoPro
3.19.1 ReoPro: Cardiovascular Monoclonal Antibody Fragment
3.19.2 ReoPro Revenue Analysis, 2008
4 Monoclonal Antibody Country Markets
4.1 Regional Overview
4.1.1 Top Eight Monoclonal Antibody Country Markets, 2008
4.1.2 US, Canada, France, Germany, Spain, Italy, UK, Japan, China & India Monoclonal Antibody Market Forecasts, 2009-2024
4.2 The US Monoclonal Antibody Therapeutics Market
4.2.1 US Market in 2008
4.2.2 US Monoclonal Antibodies Sales Forecast, 2009-2024
4.3 European Monoclonal Antibody Therapeutics Market
4.4 Monoclonal Antibodies in Emerging Markets
5 The Monoclonal Antibody Therapeutic Pipeline
5.1 Late-Stage Oncology Pipeline: Additional and Expanded Indications
5.1.1 Avastin
5.1.2 MabThera/Rituxan
5.1.3 Erbitux
5.1.4 Tysabri
5.2 Late-Stage Oncology Pipeline: Novel Entities
5.2.1 Arzerra (Ofatumumab)
5.2.2 Farletuzumab (MORAb-003)
5.2.3 Figitumumab (CP-751871)
5.2.4 Galiximab
5.2.5 Ipilimumab
5.2.6 Ramucirumab (IMC 1121B)
5.2.7 Rencarex (WX-G250)
5.2.8 Zalutumumab (HuMax-EGFr)
5.2.9 Lumiliximab
5.2.10 Pertuzumab (R1273)
5.3 Late-Stage Autoimmune Disorder Pipeline: Additional and Expanded Indications
5.3.1 Actemra/RoActemra
5.3.2 MabThera/Rituximab
5.3.3 Alemtuzumab for Multiple Sclerosis
5.4 Late-Stage Autoimmune Disorder Pipeline: New Entities
5.4.1 Ilaris (Canakinumab)
5.4.2 Stelara (Ustekinumab)
5.4.3 Simponi (Golimumab)
5.4.4 Bapineuzumab ((AAB-001)
5.4.5 Benlysta (Belimumab)
5.4.6 ABT-874
5.4.7 Mycograb (Efungumab)
5.4.8 Ocrelizumab (R1594)
5.4.9 Otelixizumab (TRX4)
5.4.10 Reslizumab (Reslizumab)
5.4.11 Solanezumab
5.4.12 Tanezumab (PF-4383119)
5.4.13 Teplizumab (MGA031)
5.4.14 Vedolizmab (MLN0002)
5.5 Other Monoclonal Antibodies Pipeline (Non-Oncology/Autoimmune Disorders)
5.5.1 Denosumab: Promising Bone Disorder Pipeline Drug
5.5.2 Denosumab: Competitor Analysis
5.5.3 Motavizumab
5.5.4 Bosatria (Mepolizumab)
5.5.5 Lucentis
5.6 Early Stage Pipeline: Antibody Fragments
5.6.1 Development and Potential of Antibody Fragments
5.6.2 Ablynx's Nanobodies: Future Cash Llama?
5.6.3 Domantis' Domain Fragments
5.6.4 Genmab's UniBodies
5.6.5 ESBATech
5.6.6 Affimed's TandAbs and Flexibodies
5.6.7 Micromet's BiTE Antibody Platform
5.7 Early Stage Pipeline: Antibody-Drug Conjugates
5.7.1 The Future of Conjugated Antibodies
5.7.2 Seattle Therapeutics
5.7.3 ImmunoGen's TAP Technology
5.7.4 Neuradiab
6 Issues Affecting the Monoclonal Antibodies Market
6.1 SWOT Chart for the Monoclonal Antibodies Industry
6.2 Strengths
6.2.1 Monoclonal Antibodies Have a Wide Range of Specific Targets
6.2.2 Chronic and Niche Diseases Generate High Revenues
6.2.3 Rich Pipeline and Manufacturing Improvements
6.2.4 Lower Risk of Adverse Events for Oncology Monoclonal Antibodies
6.3 Weaknesses
6.3.1 Biosimilar Monoclonal Antibodies
6.3.2 Future Prospects for Biosimilar Monoclonal Antibodies
6.3.3 High Development Cost Limits Growth
6.3.4 Injections are the Main Mode of Administration
6.3.5 The Challenge of Immunogenicity Still Looms Large
6.3.6 Competition is Fierce for Many Targets
6.3.7 Insufficient Efficacy of Oncology Monoclonal Antibodies as Monotherapy
6.4 Opportunities
6.4.1 Increasing Cancer Prevalence
6.4.2 Autoimmune Disorder Prevalence and Under-Treatment
6.5 Threats
6.5.1 Lack of Reimbursement for Monoclonal Antibodies
6.5.2 High Profile Safety Cases Increase Regulatory Concerns
6.5.3 Current Financial Limitations in Research and Development
7 Interviews with Monoclonal Antibody Industry Key Opinion Leaders
7.1 Dr Debbie Law, Chief Scientific Officer, and Eva-Lotta Allan, Chief Business Office, Ablynx
7.1.1 Future Prospects for Full-Size Monoclonal Antibodies, Conjugated Antibodies and Fragment Antibodies
7.1.2 Nanobodies
7.1.3 Immunogenicity of Nanobodies
7.1.4 Ablynx's Anti-Thrombotic Nanobody Pipeline
7.1.5 Anti-TNF and Anti-RANKL Nanobodies
7.1.6 Potential Advantages of Anti-Thrombotic Nanobodies
7.1.7 Multi-Valency and Multi-Specificity: Nanobodies as Building Blocks
7.1.8 New Delivery Methods
7.1.9 Future Commercial Direction of Monoclonal Antibody and Antibody Fragments
7.2 Janice M. Reichert, PhD, Senior Research Fellow at Tufts University
7.2.1 Major Challenges and Opportunities for Monoclonal Antibody Cancer Therapeutics
7.2.2 Side-Effects of Monoclonal Antibodies for Cancer
7.2.3 Future Developments and Pipelines
7.2.4 The Effect of Biosimilars
7.3 David Blakey, PhD, Chief Scientist, Cancer & Infection Research Area, AstraZeneca
7.3.1 The Future of Humanised and Fully-Human Antibodies
7.3.2 Therapeutic Antibody Fragments Versus Full-Length Antibodies
7.3.3 Major Opportunities in Monoclonal Antibody Cancer Therapeutics
8 Conclusions
8.1 Monoclonal Antibodies Account for Over 30% of Biologic Drug Revenues
8.2 Future Prospects for the Monoclonal Antibody Market
8.3 The Monoclonal Antibody Pipeline
8.4 Recent High Growth Rates Set to Continue to 2014
8.5 Market Forecast, 2014-2024
8.6 Expansion into New Markets
8.7 Future Outlook
List of Tables
Table 2.1 Monoclonal Antibody Technology
Table 2.2 Modes of Action for Monoclonal Antibody Therapeutics
Table 2.3 Monoclonal Antibody Therapeutics Approved by US FDA, 1986-2003
Table 2.4 Monoclonal Antibody Therapeutics Approved by US FDA, 2003-2009
Table 3.1 Monoclonal Antibody Sales by Therapeutic Area, 2008
Table 3.2 Sales of Leading Monoclonal Antibodies, 2008
Table 3.3 Monoclonal Antibody Sales by Technology Type, 2008
Table 3.4 Sales of Monoclonal Antibodies by Antibody Type, 2008
Table 3.5 Sales of Monoclonal Antibodies by Marketing Company, 2008
Table 3.6 Monoclonal Antibody Therapeutic Market, Drivers & Restraints, 2009-2024
Table 3.7 Total, Oncology, Autoimmune Disorder and Other Monoclonal Antibodies Sales Forecasts, 2009-2014
Table 3.8 Total, Oncology, Autoimmune Disorder and Other Monoclonal Antibodies Sales Forecasts, 2015-2024
Table 3.9 Sales of Leading Oncology Monoclonal Antibodies, 2008
Table 3.10 Sales by Technology Type, Oncology Monoclonal Antibodies, 2008
Table 3.11 Sales by Antibody Type, Oncology Monoclonal Antibodies, 2008
Table 3.12 Sales by Marketing Company, Oncology Monoclonal Antibodies, 2008
Table 3.13 Oncology Monoclonal Antibodies, Drivers & Restraints, 2009-2024
Table 3.14 MabThera/Rituxan, Avastin, Herceptin, Erbitux & Total Oncology Monoclonal Antibodies Sales Forecasts, 2009-2014
Table 3.15 MabThera/Rituxan, Avastin, Herceptin, Erbitux & Total Oncology Monoclonal Antibodies Sales Forecasts, 2015-2024
Table 3.16 MabThera/Rituxan Sales by Marketing Company, 2008
Table 3.17 MabThera/Rituxan Sales by Country, 2008
Table 3.18 MabThera/Rituxan Total, Oncology & Autoimmune Disorder Sales Forecast, 2009-2014
Table 3.19 MabThera/Rituxan Total, Oncology & Autoimmune Disorder Sales Forecast, 2015-2024
Table 3.20 MabThera/Rituxan, Drivers & Restraints, 2009-2024
Table 3.21 Avastin Sales by Marketing Company, 2008
Table 3.22 Avastin Sales by Country, 2008
Table 3.23 Avastin, Drivers & Restraints, 2009-2024
Table 3.24 Herceptin Sales by Marketing Company, 2008
Table 3.25 Herceptin Sales by Country, 2008
Table 3.26 Herceptin, Drivers & Restraints, 2009-2024
Table 3.27 Erbitux Sales by Marketing Company, 2008
Table 3.28 Erbitux Sales by Country, 2008
Table 3.29 Erbitux, Drivers & Restraints, 2009-2024
Table 3.30 Major Nimotuzumab Markets, 2009
Table 3.31 Sales of Leading Autoimmune Disorder Monoclonal Antibodies, 2008
Table 3.32 Sales by Technology Type, Autoimmune Disorder Monoclonal Antibodies, 2008
Table 3.33 Sales by Antibody Type, Autoimmune Disorder Monoclonal Antibodies, 2008
Table 3.34 Sales by Marketing Company, Autoimmune Disorder Monoclonal Antibodies, 2008
Table 3.35 Autoimmune Disorder Monoclonal Antibodies, Drivers & Restraints, 2009-2024
Table 3.36 Remicade, Humira, Simponi, Cimzia & Total Autoimmune Disorder Monoclonal Antibodies Sales Forecasts, 2009-2014
Table 3.37 Remicade, Humira, Simponi, Cimzia & Total Autoimmune Disorder Monoclonal Antibodies Sales Forecasts, 2015-2024
Table 3.38 Remicade Sales by Marketing Company, 2008
Table 3.39 Remicade Sales by Country, 2008
Table 3.40 Remicade, Drivers & Restraints, 2009-2024
Table 3.41 Approved Indications for Humira in the US
Table 3.42 Humira Sales by Marketing Company, 2008
Table 3.43 Humira Sales by Country, 2008
Table 3.44 Humira, Drivers & Restraints, 2009-2024
Table 3.45 Cimzia, Drivers & Restraints, 2009-2024
Table 3.46 Simponi, Drivers & Restraints, 2009-2024
Table 3.47 MabThera/Rituxan (Autoimmune Indications), Xolair & Tysabri Sales Forecasts, 2009-2014
Table 3.48 MabThera/Rituxan (Autoimmune Indications), Xolair, & Tysabri Sales Forecasts, 2015-2024
Table 3.49 Tysabri Sales by Country, 2008
Table 3.50 Sales of Leading Other Monoclonal Antibodies (Non-Oncology/Autoimmune Disorders), 2008
Table 3.51 Lucentis, Synagis/Motavizumab and Other Non-Oncology/Autoimmune Disorder Monoclonal Antibodies Sales Forecasts, 2009-2014
Table 3.52 Lucentis, Synagis/Motavizumab and Other Non-Oncology/Autoimmune Disorder Monoclonal Antibodies Sales Forecasts, 2015-2024
Table 3.53 Lucentis Sales by Marketing Company, 2008
Table 3.54 Lucentis Sales by Country, 2008
Table 3.55 Drivers and Restraints on Lucentis Revenues, 2009-2014
Table 3.56 Synagis Sales by Marketing Company, 2008
Table 3.57 Synagis Sales by Country, 2008
Table 4.1 Leading Eight Monoclonal Antibody Therapeutics Markets, 2008
Table 4.2 US, Canada, France, Germany, Spain, Italy, UK, Japan, China & India Monoclonal Antibody Market Forecasts, 2009-2024
Table 4.3 US Monoclonal Antibody Sales by Therapeutic Area, 2008
Table 4.4 Leading Ten US Monoclonal Antibodies, 2008
Table 5.1 Oncology Pipeline: Additional Indications for Avastin
Table 5.2 Oncology Pipeline: Additional Indications for Approved Drugs (Other than Avastin)
Table 5.3 Oncology Pipeline: Selected New Entities in Phase III or Regulatory/Submission
Table 5.4 Oncology Pipeline: Selected New Entities in Phase II, Part 1
Table 5.5 Oncology Pipeline: Selected New Entities in Phase II, Part 2
Table 5.6 Autoimmune Disorders Pipeline: Additional Indications for Approved Drugs
Table 5.7 Autoimmune Disorder Pipeline: Selected New Entities in Phase III/Regulatory Submission: Part 1
Table 5.8 Autoimmune Disorder Pipeline: Selected New Entities in Phase III/Regulatory Submission: Part 2
Table 5.9 Autoimmune Disorder Pipeline: Selected New Entities in Phase II
Table 5.10 Pipeline for Other Monoclonal Antibodies (Non-Oncology/Autoimmune Disorders)
Table 5.11 Antibody Fragment Pipeline
Table 5.12 Antibody-Cytotoxic Drug Conjugate Pipeline: Part 1
Table 5.13 Antibody-Cytotoxic Drug Conjugate Pipeline: Part 2
Table 6.1 SWOT Chart for the Monoclonal Antibody Therapeutics Industry, 2009-2024
Table 6.2 Monoclonal Antibody Targets
Table 6.3 Expected Patent Expiries for Monoclonal Antibodies
Table 6.4 Biosimilar Monoclonal Antibodies in Development
List of Figures
Figure 2.1 Antibody Structure
Figure 3.1 Monoclonal Antibody Therapeutic Area Market Share, 2008
Figure 3.2 Leading Monoclonal Antibodies Market Share, 2008
Figure 3.3 Monoclonal Antibody Technology Type Market Share, 2008
Figure 3.4 Monoclonal Antibody Type Market Share, 2008
Figure 3.5 Monoclonal Antibody Marketing Company Market Share, 2008
Figure 3.6 Total Monoclonal Antibodies Sales Forecast, 2009-2024
Figure 3.7 Oncology, Autoimmune Disorder and Other Monoclonal Antibodies Sales Forecasts, 2009-2024
Figure 3.8 Oncology, Autoimmune Disorder and Other Monoclonal Antibodies Market Share, 2009-2024
Figure 3.9 Leading Oncology Monoclonal Antibodies Market Share, 2008
Figure 3.10 Technology Type Market Share, Oncology Monoclonal Antibodies, 2008
Figure 3.11 Antibody Type Market Share, Oncology Monoclonal Antibodies, 2008
Figure 3.12 Marketing Company Market Share, Oncology Monoclonal Antibodies, 2008
Figure 3.13 Total Oncology Monoclonal Antibodies Sales Forecast, 2009-2024
Figure 3.14 MabThera/Rituxan, Avastin, Herceptin and Erbitux & Other Oncology Monoclonal Antibodies Market Share, 2009-2024
Figure 3.15 MabThera/Rituxan Marketing Company Market Share, 2008
Figure 3.16 MabThera/Rituxan Country Market Share, 2008
Figure 3.17 MabThera/Rituxan Total, Oncology & Autoimmune Disorder Sales Forecast, 2009-2024
Figure 3.18 Avastin Marketing Company Market Share, 2008
Figure 3.19 Avastin Country Market Share, 2008
Figure 3.20 Avastin Sales Forecast, 2009-2024
Figure 3.21 Herceptin Marketing Company Market Share, 2008
Figure 3.22 Herceptin Country Market Share, 2008
Figure 3.23 Herceptin Sales Forecast, 2009-2024
Figure 3.24 Erbitux Marketing Company Market Share, 2008
Figure 3.25 Erbitux Sales Country Market Share, 2008
Figure 3.26 Erbitux Sales Forecast, 2009-2024
Figure 3.27 Leading Autoimmune Disorder Monoclonal Antibodies Market Share, 2008
Figure 3.28 Technology Type Market Share, Autoimmune Disorder Monoclonal Antibodies, 2008
Figure 3.29 Antibody Type Market Share, Autoimmune Disorder Monoclonal Antibodies, 2008
Figure 3.30 Marketing Company Market Share, Autoimmune Disorder Monoclonal Antibodies, 2008
Figure 3.31 Total Autoimmune Disorder Monoclonal Antibodies Sales Forecast, 2009-2024
Figure 3.32 Remicade, Humira, Simponi, & Other Autoimmune Disorder Monoclonal Antibodies Market Share, 2009-2024
Figure 3.33 Remicade Marketing Company Market Share, 2008
Figure 3.34 Remicade Country Market Share, 2008
Figure 3.35 Remicade Sales Forecast, 2009-2024
Figure 3.36 Humira Marketing Company Market Share, 2008
Figure 3.37 Humira Country Market Share, 2008
Figure 3.38 Humira Sales Forecast, 2009-2024
Figure 3.39 Cimzia Sales Forecast, 2009-2024
Figure 3.40 Simponi Sales Forecast, 2009-2024
Figure 3.41 Xolair Sales Forecast, 2009-2024
Figure 3.42 Tysabri Country Market Share, 2008
Figure 3.43 Tysabri Sales Forecast, 2009-2024
Figure 3.44 Total Non-Oncology/Autoimmune Disorder Monoclonal Antibodies Sales Forecast, 2009-2024
Figure 3.45 Lucentis Marketing Company Market Share, 2008
Figure 3.46 Lucentis Country Market Share, 2008
Figure 3.47 Lucentis Sales Forecast, 2009-2024
Figure 3.48 Synagis Marketing Company Market Share, 2008
Figure 3.49 Synagis Country Market Share, 2008
Figure 3.50 Synagis/Motavizumab Sales Forecast, 2009-2024
Figure 4.1 Leading Eight Monoclonal Antibody Therapeutics Markets, 2008
Figure 4.2 US, Canada, France, Germany, Spain, Italy, UK, Japan, China & India Monoclonal Antibody Market Forecasts, 2009-2024
Figure 4.3 US Monoclonal Antibody Sales by Therapeutic Area, 2008
Figure 4.4 Leading Ten US Monoclonal Antibodies, 2008
Figure 4.5 US Monoclonal Antibodies Sales Forecast, 2009-2024
Figure 5.1 Antibody Fragment Types
Figure 8.1 World Monoclonal Antibody Therapeutics Market Forecast, 2009-2024
Companies Mentioned:
Abbott
Abgenix (acquired by Amgen, 2006)
Ablynx
Actinium
Affimed Therapeutics
Alcon (Nestlé)
Alexion
Amgen
Arana Therapeutics
AstraZeneca
Bayer
Biocon
Biogen (merged with IDEC in 2003 to form Biogen Idec)
Biogen Idec
BioTech Pharma [Chinese/Cuban joint venture]
Biotest
Boehringer Ingelheim
Bradmer
Bristol-Myers Squibb
Cambridge Antibody Technology (CAT) (acquired by AstraZeneca)
Cell Therapeutics
Celltech (acquired by UCB, 2004)
Center of Molecular Immunology [Cuba]
Centocor (acquired by Johnson & Johnson, 1999)
Cephalon
Ception Therapeutics
Chugai (majority-owned by Roche)
Committee for Medicinal Products for Human Use (CHMP) (part of EMEA)
Corixa (acquired by GSK, 2005)
Daiichi-Sankyo
Dainippon Sumitomo
Domantis (acquired by GSK, 2007)
Dr. Reddy's Laboratories
Eisai
Elan
Eli Lilly
ESBATech
Esteve
Eurofarma [Brazil]
European Medicines Agency (EMEA)
Facet Biotech (formerly part of PDL BioPharma)
Food and Drug Administration (FDA) [US]
Fresenius
Genentech (acquired by Roche in March 2009)
Genmab
Genzyme
GSK (GlaxoSmithKline)
GTC Biotherapeutics
Health Canada
Human Genome Sciences
IDEC (merged with Biogen in 2003 to form Biogen Idec)
Ilex Oncology (acquired by Genzyme, 2004)
ImClone (acquired by Eli Lilly, November 2008)
ImmunoGen
Immunomedics
Implicit Bioscience
Johnson & Johnson
Kyowa Hakko Kirin
Laboratorio Elea [Argentina]
LFB Biotechnologies
Ludwig Institute for Cancer Research
MacroGenics
Medarex
MedImmune (acquired by AstraZeneca, 2007)
Menarini
Merck & Co.
Merck KGaA
Micromet
Millennium (acquired by Takeda, 2008)
Ministry of Health, Labour and Welfare (MHLW) [Japan]
Mitsubishi Tanabe
Morphotek (acquired by Eisai, 2007)
National Cancer Institute (NCI, part of NIH) [US]
National Eye Institute (NEI, part of NIH) [US]
National Institutes of Health (NIH) [US]
NeuTec (acquired by Novartis, 2006)
Novartis
Nycomed
Oncoscience
Onyx
Osaka University
Otsuka
PDL BioPharma
Peregrine
Pfizer
Pierre Fabre
Progenics
Ranbaxy
Rinat (acquired by Pfizer, 2006)
Roche
Roche Group (Roche, Genentech & Chugai)
Sanofi-Aventis
Schering-Plough
Seattle Genetics
Shanghai Medipharm Biotech (Medipharm)
Shantha Biotechnics
Spectrum
State Food and Drug Administration (SFDA) [China]
Takeda
Tanox (acquired by Genentech in 2007
Tolerx
Trion
UCB
University of Massachusetts Medical School
Viventia
Wilex
Wyeth
Xoma
YM Biosciences
Zenotech
Zenyaku Kogyo
